We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...
Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.22 | -14.8648648649 | 1.48 | 1.48 | 1.23 | 192771 | 1.33692174 | CS |
4 | 0 | 0 | 1.26 | 1.675 | 1.23 | 443365 | 1.44786354 | CS |
12 | 0.2 | 18.8679245283 | 1.06 | 1.675 | 0.975 | 521623 | 1.22945921 | CS |
26 | -0.75 | -37.3134328358 | 2.01 | 3.07 | 0.87 | 549438 | 1.23969274 | CS |
52 | -19.02 | -93.7869822485 | 20.28 | 22.22 | 0.87 | 432598 | 2.50341159 | CS |
156 | -15.59 | -92.5222551929 | 16.85 | 23.58 | 0.87 | 197763 | 4.4946569 | CS |
260 | -15.59 | -92.5222551929 | 16.85 | 23.58 | 0.87 | 197763 | 4.4946569 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions